Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845441 · ClinicalTrials.gov registry record · Phase 2
Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions
A Phase 2 study, sponsored by University Hospitals Cleveland Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01845441 is a Phase 2 study that was terminated before completion, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 7 participants.
The verdict
NCT01845441, a Phase 2 study, was terminated before completion, sponsored by University Hospitals Cleveland Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Dexmedetomidine is a unique sedative medication able to provide sedation without causing respiratory depression and maintaining neurological functions. Patients having an acute ischemic stroke and need to undergo endovascular therapy require constant assessment of their neurological status prior, during and after the interventional procedure. In this study the investigators will compare the efficacy of Dexmedetomidine to other standard sedative medications in providing optimal sedative effect while maintaining neurological function.
Interventions
- DRUG Midazolam
- DRUG Dexmedetomidine
- DRUG Fentanyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2012-04 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845441
The ClinicalTrials.gov registry entry for NCT01845441 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University Hospitals Cleveland Medical Center, which has 230 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT01845441 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845441 about?
NCT01845441 is a clinical study titled "Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions". Dexmedetomidine is a unique sedative medication able to provide sedation without causing respiratory depression and maintaining neurological functions. Patients having an acute ischemic stroke and need to undergo endovascular therapy require constant assessment of their neurological status prior, du...
What is the current status of trial NCT01845441?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2012-04. Estimated completion is 2021-12.
What interventions are being tested in trial NCT01845441?
The interventions under investigation include: Midazolam (DRUG), Dexmedetomidine (DRUG), Fentanyl (DRUG).
Who is sponsoring clinical trial NCT01845441?
This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.